Source: International Congress 2018 – Innovative therapies in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Buhl (Mainz, Germany), L. Heaney (Belfast, United Kingdom), E. Loefroth (Täby, Sweden), P. Larbig (Basel, Switzerland), K. Kostikas (Basel, Switzerland), V. Conti (Basel, Switzerland), H. Cao (East Hanover, United States of America). Disease control and treatment pathways of asthma patients after initiating ICS/LABA. 613

Member's Comments

No comment yet.

Related content which might interest you: Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021 Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Cost burden in COPD patients initiating ICS vs. non-ICS maintenance regimens Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 The response to combination therapy treatment regimens in severe/difficult-to-treat asthma Source: Eur Respir J 2008; 32: 1237-1242 Year: 2008 Predictive factors for asthma control according to ACQ5 in asthma patients treated with budesonide/formoterol maintenance and reliever therapy. Results from the EuroSMART study Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Factors influencing LAMA addition to COPD patients receiving ICS/LABA in clinical practice-RETRIEVE study. Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Sputum assessment in asthma management does not improve disease control when GINA step-up treatment is used in mild-to-moderate patients Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Control of persistent asthma patients on inhaled corticosteroids in a real-life setting Source: Annual Congress 2010 - New insights in the epidemiology of asthma Year: 2010 Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 The add-on effect of tiotropium bromide to ICS/LABA combination inhaler for the patients with severe uncontrolled asthma Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Adherence with two types of inhaled corticosteroids as a primary controller regimen in adult asthma patients Source: Eur Respir J 2002; 20: Suppl. 38, 304s Year: 2002 Patients‘ reasons for early discontinuation of inhaled corticosteroids and their disease control Source: Eur Respir J 2007; 30: Suppl. 51, 285s Year: 2007 Assessment of maximal airway response before and after inhaled corticosteriod treatment in new diagnosed asthma patients Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Combination therapy of ICSs/LABAs plus montelucastin patients with severe asthma Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015